Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 1 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Recs

0
Player Avatar Frimax32 (< 20) Submitted: 1/4/2013 12:09:59 PM : Outperform Start Price: $6.10 DNDN Score: -112.72

I understand they bottomed out and FDA has become tolerant

Featured Broker Partners


Advertisement